The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1392
June 11, 2012
View Complete Issue         Table of Contents 2019 
Peginesatide (Omontys) for Anemia in Chronic Kidney Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Peginesatide (Omontys) for Anemia in Chronic Kidney Disease
June 11, 2012 (Issue: 1392)
The FDA has approved the erythropoiesis-stimulating agent (ESA) peginesatide (Omontys – Affymax/Takeda), a synthetic peptide analog of erythropoietin, for treatment of anemia in patients with chronic kidney disease (CKD) who are on dialysis....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Peginesatide (Omontys) for Anemia in Chronic Kidney Disease
Article code: 1392b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.